WallStSmart

Medline Inc. Class A Common Stock (MDLN)vsNephros Inc (NEPH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 152274% more annual revenue ($29.14B vs $19.12M). NEPH leads profitability with a 4.1% profit margin vs 3.3%. MDLN trades at a lower P/E of 31.4x. MDLN earns a higher WallStSmart Score of 55/100 (C-).

MDLN

Buy

55

out of 100

Grade: C-

Growth: 7.3Profit: 5.5Value: 4.7Quality: 6.5
Piotroski: 4/9Altman Z: 1.79

NEPH

Avoid

32

out of 100

Grade: F

Growth: 6.0Profit: 4.5Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -10.50
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MDLN.

NEPHUndervalued (+6.9%)

Margin of Safety

+6.9%

Fair Value

$4.34

Current Price

$3.42

$0.92 discount

UndervaluedFair: $4.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDLN2 strengths · Avg: 9.0/10
EPS GrowthGrowth
1258.0%10/10

Earnings expanding 1258.0% YoY

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

NEPH1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0910/10

Conservative balance sheet, low leverage

Areas to Watch

MDLN4 concerns · Avg: 3.5/10
P/E RatioValuation
31.4x4/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.794/10

Distress zone — elevated risk

Profit MarginProfitability
3.3%3/10

3.3% margin — thin

Debt/EquityHealth
1.123/10

Elevated debt levels

NEPH4 concerns · Avg: 3.0/10
Market CapQuality
$36.80M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
7.3%3/10

ROE of 7.3% — below average capital efficiency

Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Operating MarginProfitability
1.9%3/10

Operating margin of 1.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : MDLN

The strongest argument for MDLN centers on EPS Growth, Price/Book. Revenue growth of 10.7% demonstrates continued momentum.

Bull Case : NEPH

The strongest argument for NEPH centers on Debt/Equity.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Altman Z-Score, Profit Margin. Thin 3.3% margins leave little buffer for downturns.

Bear Case : NEPH

The primary concerns for NEPH are Market Cap, Return on Equity, Profit Margin. A P/E of 48.4x leaves little room for execution misses. Thin 4.1% margins leave little buffer for downturns.

Key Dynamics to Monitor

MDLN is growing revenue faster at 10.7% — sustainability is the question.

MDLN generates stronger free cash flow (316M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDLN scores higher overall (55/100 vs 32/100) and 10.7% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Nephros Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Nephros, Inc., a commercial stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company is headquartered in South Orange, New Jersey.

Want to dig deeper into these stocks?